Paula J. Busse MD is an Associate Professor in the Department of Medicine, Division of Clinical Immunology. She received her undergraduate education at Wellesley College and her medical degree from the University of Rochester. She completed her medical residency training in Internal Medicine and her post-doctorate training in Allergy and Immunology at the Mount Sinai School of Medicine, where she also completed a graduate clinical research training program. Her clinical and research areas of interest are asthma in older patients and treatment of hereditary angioedema. Dr. Busse is funded by the National Institutes of Health and several foundation grants. She is active in the American Academy of Allergy, Asthma and Immunology, giving lectures at national and local meetings and is involved in several of its committees. She has been elected to the Hereditary Angioedema Association Scientific Medical Advisory Board. She has been a small group discussion leader for the first-year medical student basic immunology course for several years.
American Board of Allergy & Immunology
MD, University of Rochester School of Medicine & Dentistry
Residency, Internal Medicine
Mount Sinai Hospital
Fellowship, Clinical Immunology
Mount Sinai Hospital
Allergy, Asthma and Immunology Education and Research Trust/Journal of Clinical Immunology Research Award
Dr. Solomon Silver Award
Clinical Medicine (MSH)
T. Franklin Williams Scholar Award
ACAAI Young Faculty Award
Asthma in older patients
Asthma morbidity and mortality is highest in patients >65 years old, and underlying airway inflammation in this age group has not been characterized. In this laboratory, we have studied a model of asthma in aged mice and have investigated whether age alters modulation of airway inflammation. Presently, the laboratory is translating these studies to evaluate clinical characteristics of asthma in older patients and markers of inflammation in the airways of these patients. This knowledge will help to direct age-specific anti-inflammatory asthma therapy.
Hereditary Angioedema (HAE)
HAE is a rare disease which affects approximately 4,000 people in the US. Its symptoms include swelling of the face, airway, extremities and abdomen. If swelling involves the airways, it can be life-threatening. Our group has been involved in several clinical trials for new medications to treat HAE. In addition, the laboratory is presently studying mechanisms by whichestrogen can exacerbate HAE.
Zuraw BL, Banerji A, Bernstein JA, Busse PJ, Christiansn SC, Davis-Lorton M, Frank MM, Li HH, Lumry WR, Riedl M. US Hereditary Angioedema Association Medical Advisory Board 2013 Recommendation for the management of Hereditary Angioedema due to C1 Inhibitor deficiency. J Allergy and Clin Immunol: In Practice 2013; 1 (6): 458-467.
Birmingham JM, Patil S, Li XM, Busse PJ. The effect of oral tolerance on the allergic airway response in young and aged mice. J Asthma 2013: 50 (2): 122-32.
Busse PJ, Cohn RD, Salo PM, Zeldin DL. Characteristics of allergic sensitization among adult asthmatics >55 years: Results from the National Health and Nutrition Examination Survey 2005-2006. Ann Allergy Asthma Immunol 2013; 110 (4) 247-52.
Riedl MA, Hurewitz DS, Levy R, Busse PJ, Fitts D, Kalfus I. Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial. Ann Allergy Asthma Immunol 2012; 108: 49-53.
Busse PJ, Lurshurchadia L, Sampson H, Halm EA, Wisnivesky J. Perennial allergen-specific immunoglobulin E levels among inner-city elderly asthmatics. J Asthma 2010; 47 (7): 781-5.
Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 Inhibitor Concentrate for treatment of hereditary angioedema. NEJM 2010; 363 (6): 513-22.
Busse PJ, Schofield B, Birmingham N, Yang N, Wen MC, Zhang T, Srivastava K, Li XM. The traditional Chinese Herbal Formula, ASHMI, inhibits allergic lung inflammation in antigen-sensitized and antigen-challenged aged mice. Ann Allergy Asthma Immunol 2010; 104 (3): 236-246.
Busse PJ, Zhang TF, Schofield B, Kilaru K, Patil S, Li XM. Decrease in airway mucous gene expression caused by treatment with anti-tumor necrosis factor alpha in a murine model of allergic asthma. Ann Allergy Asthma Immunol 2009; 103 (4): 295-303.
Busse PJ, Zhang, TF, Srivastava K, Schofield B, Li XM. Effect of ageing on pulmonary inflammation, airway hyperresponsiveness and T and B cell responses in antigen-sensitized and -challenged mice. Clin Exp Allergy 2007; 37 (9): 1392-1403.
Anti IL-5 (Mepolizumab) treatment in hypereosinophilic syndrome
CSL Behring, Viropharma/Shire, Dyax Corp, Gerson Lehrman Group
A Compassionate Use Open-Label Study of Anti IL-5 (Mepolizumab) Treatment in Subjects with Hypereosinophilic Syndrome
Mepolizumab is being developed by GlaxoSmithKline and is a type of biologic drug called a monoclonal antibody that can block the actions of a protein molecule called interleukin 5 (IL-5). IL-5 is thought to increase the level of eosinophils, a type of white blood cell, in the blo...
HELP Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate DX-2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)
The purpose of this study is to:
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Busse during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.